There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

When researchers analyzed weight loss results from patients who took GLP-1 drugs and those who'd undergone bariatric surgery, one method led to much more weight loss.

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses of its blockbuster weight loss medicine Zepbound.

With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay ...

About Zepbound (tirzepatide) injection Zepbound is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication.

Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month ...

About Zepbound (tirzepatide) injection Zepbound is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication.

After 72 weeks, participants receiving the Zepbound injections lost an average of 50 pounds, or 20% of their body weight. In contrast, Weogovy users lost an average of 33 pounds or 14% of their ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its push to lower prescription drug prices.